Overview

Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

Status:
Recruiting
Trial end date:
2035-06-04
Target enrollment:
Participant gender:
Summary
This is a phase I/II, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult with R/R Non-Hodgkins Lymphoma in China.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Beijing Immunochina Medical Science & Technology Co., Ltd.
Collaborator:
Jiangsu Simcere Pharmaceutical Co., Ltd.
Treatments:
Cyclophosphamide
Fludarabine